Apellis Pharmaceuticals Acquired by Biogen | Healthcare M&A Deal

Biogen has completed the acquisition of Apellis Pharmaceuticals, a pharmaceuticals business in New York, for $5.3B. Apellis Pharmaceuticals develops targeted therapies for complement-mediated diseases, strengthening Biogen’s neuroscience and immunology pipeline. Biogen acquisitions in healthcare M&A aim to expand late-stage drug development and diversify revenue streams through a strategic acquisition in NY. The platform acquisition is categorized as a strategic acquisition and closed, with deal size reported at $5.3 billion, supporting Biogen acquisitions and broader pharmaceuticals acquisition strategy.